Pfizer Ltd vs Valiant Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Pfizer Ltd is ₹ 4708 as of 30 Apr 15:30 . The P/E Ratio of Pfizer Ltd is 0 as of March 2023 .The P/E Ratio of Valiant Laboratories Ltd is 0 as of March 2023 . The Market Cap of Pfizer Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Valiant Laboratories Ltd is ₹ 0 crore as of March 2023 . The revenue of Pfizer Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Valiant Laboratories Ltd for the Dec '25 is ₹ 53.09 crore as compare to the Sep '25 revenue of ₹ 47.07 crore. This represent the growth of 12.79% The ebitda of Pfizer Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Valiant Laboratories Ltd for the Dec '25 is ₹ -0.26 crore as compare to the Sep '25 ebitda of ₹ 0.94 crore. This represent the decline of -127% The net profit of Pfizer Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Valiant Laboratories Ltd changed from ₹ -0.51 crore to ₹ -7.06 crore over 7 quarters. This represents a CAGR of 348.88% The Dividend Payout of Pfizer Ltd changed from 32.18 % on March 2021 to 98.34 % on March 2025 . This represents a CAGR of 25.03% over 5 yearsThe Dividend Payout of Valiant Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Pfizer Ltd

Pfizer Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
The Company offer a portfolio of 150 specialised medicines in 15 therapeutic areas across 4 business categories.
It has its own manufacturing facility at Goa and Thane.
It has the distinction of being the first pharmaceutical company in India to start clinical research.
The Company sells products in nearly 185 countries having 43 manufacturing sites globally.

About Valiant Laboratories Ltd

Valiant Laboratories Limited was originally formed as a Partnership Firm as M/s.
Bharat Chemicals' through deed of partnership dated October 17, 1980.
The said Partnership Firm, M/s.
Bharat Chemicals thereafter converted into a Public Company to 'Valiant Laboratories Limited' via Certificate of incorporation dated August 16, 2021 issued by the Central Registration Centre, Registrar of Companies. The Company is an Active Pharmaceutical Ingredient (API) / Bulk Drug manufacturing company having focus on manufacturing of Paracetamol.
The Company gradually, commenced manufacturing of Paracetamol by late 1982.

FAQs for the comparison of Pfizer Ltd and Valiant Laboratories Ltd

Which company has a larger market capitalization, Pfizer Ltd or Valiant Laboratories Ltd?

Market cap of Pfizer Ltd is 21,538 Cr while Market cap of Valiant Laboratories Ltd is 428 Cr

What are the key factors driving the stock performance of Pfizer Ltd and Valiant Laboratories Ltd?

The stock performance of Pfizer Ltd and Valiant Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Pfizer Ltd and Valiant Laboratories Ltd?

As of May 4, 2026, the Pfizer Ltd stock price is INR ₹4708.15. On the other hand, Valiant Laboratories Ltd stock price is INR ₹78.85.

How do dividend payouts of Pfizer Ltd and Valiant Laboratories Ltd compare?

To compare the dividend payouts of Pfizer Ltd and Valiant Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.